Michael Rome

Dr. Michael Rome joined Foresite Capital in 2016 and co-leads the therapeutics investing practice. Michael is a board director at Kinnate Biopharma, Pharvaris, and Remix Therapeutics, with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, PACT Pharma, and Nurix Therapeutics. Michael served as Vice President for Foresite Development Corporation (FSDC) and has led investments in several public companies across the portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies.